ACADIA Pharmaceuticals Inc. (ACAD)

Several events have impacted ACADIA's stock price in the past six months. The FDA approved DAYBUE STIX in December 2025, with a limited U.S. launch in Q1 2026 and a broader launch planned for Q2 2026. ACADIA reported strong revenue growth in its fourth quarter and full year 2025 financial results in February 2026, surpassing $1 billion in annual revenue for the first time. However, the EMA issued a negative trend vote on its Marketing Authorization Application for trofinetide (DAYBUE) for Rett syndrome, causing a stock setback. In early April 2026, BofA Securities upgraded ACADIA's stock rating to Buy, while lowering its price target to $29 from $31, and RBC Capital also lowered its price target to $29 from $30. Additionally, on April 7, 2026, Executive Vice President and CFO Mark C. Schneyer sold 2,709 shares of common stock.

ACADIA Pharmaceuticals has noted a "seasonal reduction in gross to net from the Medicare Part D redesign" in the first quarter of 2025 for NUPLAZID, indicating that demand or net sales can experience seasonal fluctuations influenced by factors related to Medicare Part D.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for central nervous system (CNS) disorders and rare diseases. Its commercial portfolio includes NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome. The company also has a pipeline of product candidates in development, targeting conditions like Prader-Willi Syndrome, Alzheimer's disease psychosis, and Lewy body dementia psychosis.

ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California, U.S. While its current commercial presence is primarily in the U.S., the company is actively pursuing international expansion for DAYBUE, with regulatory approvals already secured in Canada and Israel. ACADIA is also working towards expanding its global reach for DAYBUE in the European Union.

ACADIA Pharmaceuticals has generally maintained a positive brand reputation, particularly as a leader in neuroscience and rare diseases. However, the negative trend vote from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorization Application for trofinetide (DAYBUE) in the European Union could negatively affect ACADIA's reputation.

ACADIA Pharmaceuticals Inc.'s ownership is significantly influenced by institutional investors, who hold over 42% of the company's stock as of July 2025. Major institutional shareholders include Baker Bros. Advisors Lp, BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Felix Baker and Baker Bros. Advisors Lp are also prominent major shareholders. Insiders collectively own 24% of the company's shares.